Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's a Red Fraggle
Puppets & Muppets
The main difference between muppets and puppets is that puppets are movable models of people or animals animated or manipulated by people while muppets are a special type of puppets. A puppet is an object that often resembles a human or animal
MYMETICS will disclose the names of all potential Transaction partners already being contacted by MYMETICS prior to the execution of this Agreement.
MYMETICS will reimburse BRESLIN in a timely manner for all reasonable additional costs and expenses, including travel expenses, subject to the prior approval by MYMETICS of at least 30 days in advance.
Let's hear it for the rich insiders
Guess we need to get a hold of the Grand Poobah
LOL
BRESLIN would like to emphasize that BRESLIN is interested in establishing a long-term contractual relationship with MYMETICS
Couldn't be exclusive this time being that there is two biotech consulting firms
So 45 grand w/ the first two months up front
In May 2022
Does that mean it's 90 grand this time around
When in May Ronnie, 8k on Tuesday ?
The first two-month payment of the Retainer Fee will be due 14 days after the execution of this Agreement.
If I had a snow pony
I'd name it San Fran 2
LOL
AGREEMENT BETWEEN MYMETICS S.A. AND BRESLIN AG
https://last10k.com/sec-filings/mymx/0001354488-15-003126.htm
https://fintel.io/doc/sec-mymx-mymetics-ex10-2015-june-24-18549-695
Earlier David was engaged with various Biotech and Venture Capital companies in San Francisco
https://www.breslin.ch/who-we-are
Come on Big Bonanza b/c I can hardly wait to see how this cheap biotech buyout pump & dump pans out
https://scholarsarchive.byu.edu/cgi/viewcontent.cgi?article=1262&context=sahs_review
LMAO
.
GiddyUp
LOL
Persons entitled The Royal Bank of Scotland PLC
Persons entitled
Barclays Bank PLC
Third party legal charge
Amount secured
All monies due or to become due from the trustees from time to time of the landmark groundworks defined contribution funded unapproved retirement benefits scheme for mr m g johnson to the chargee on any account whatsoever
Short particulars
Flat 1 swallowfields 34 lovelace gardens surbiton surrey. By way of fixed charge the benefit of all covenants and rights concerning the property and plant machinery fixtures fittings furniture equipment implements and utensils the goodwill of any business carried on at the property and the proceeds of any insurance affecting the property or assets.
Additional transactions filed against this charge
Type(of transaction) Delivered(to Companies House on this date)
Statement of satisfaction of a charge in full or part (403a) 20 April 2009
View PDF
for Statement of satisfaction of a charge in full or part (403a) (2 pages)
https://s3.eu-west-2.amazonaws.com/document-api-images-live.ch.gov.uk/docs/gy6lwJYrxJteWKIqxZol8GXgLuLjEze_6hQfnvZvs20/application-pdf?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAWRGBDBV3JYGFE2UB%2F20220507%2Feu-west-2%2Fs3%2Faws4_request&X-Amz-Date=20220507T194146Z&X-Amz-Expires=60&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEPb%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCWV1LXdlc3QtMiJIMEYCIQCkjCveCyOzUiVnN3DjUeuN4LXbwpMhjaY1oyMumJxGTgIhAPgJXcuUiOD84anMqvQppcB%2BckhDOrvZGDH22EUhp7BOKtwECL%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEQBBoMNDQ5MjI5MDMyODIyIgxod6rgoK%2F5V2WHOaMqsAT2PrOkBGGe3zT7n8%2BN%2BTXcTlTMQ60k1b3j6IN169wZJhcVnsiaZVb0uKVS8QXbU9GLQ%2F8Mqd98uUXb8j%2BogmERFf3L7UPqMnF%2BKDKhdXCMXxB%2FejiG3s2r0t9dxCpAD9NGcyNSUmoR4YbQ3EFeb0RoxAm94D7PX2rI8VLWUSe8Qmdxz%2BIk19ibVwx1WGr4jGUZGS6tzFTGzqoPETJM9uRwkBcYZoZ7M29F4Dly8U4oOS%2BYigolIdRjTMWyWv2TlMy0A6GZYIJz0BPj6BM7d3pO0IA0XVEltXH95KKz%2FU2bmnMCLbq%2BPQAix5LR0Bk57YmbC0XvFjjiccUKbCBj4NbF6nZkplLEvlwDuzgGmxkZP6tdzpEWFOXOqTQ46BOzVVBy3T5d3IITorewfOeBZt1mMMqxS2UwBZ2Mu8AV1HN99cozrZJ8f7aiAoY6NP2VIGgZ20aCt8k4yKByUhDnuaosRv4j57B4bgN832npmLRaKRauI50ZgCNRQZw6Lm8prXUlTWX%2Fm9ou5mvuVjnVLrCZ%2FcFiR7HamCAZyijmleSfmu3T27QCPiHReQNbsycvKnh1iQwRyU4h%2BZupBzUOt%2BtOifIC9p6G8n9gyk6WIc5F3tGNM0%2BxgDxe00LIPI2FUYFa2%2B%2FtP0Tx4R4GBXIwc37h0wn%2FykKd%2BnKRyMZmc5ORckHFjILXp69yRALTP43AIscIpr6ApS37%2BHCVJk6u1OqqTs2HVvXnKjvWzf8kfIIWqDDF8NmTBjqoAaDZtiaMPZtK08283IH0M3iNH1rlYZB23gHyGEyPJgx2igN%2FmuG%2F75ON4DyK8nsrWCpHO2c0grtLrUnBUoe9d2DOlhK29LkePWvdAswE1nB2kpHOcRaI6TRASKSrHo9VyHsEcot4xbNHEkbRGJZ7lJDp%2FcFkXKp1YoZrthcoEsgWIvc%2BSkeCuc7AGU%2BV7ntDMhe%2BVnbogYgsZAkL8o%2F0b84LFwAq8IYV%2Bw%3D%3D&X-Amz-SignedHeaders=host&response-content-disposition=inline%3Bfilename%3D%22companies_house_document.pdf%22&X-Amz-Signature=edf908f879391760d8e1e9a1ebce1b82e46ae111570173ad93470125434b9f38
70 gracechurch street london ec3v 0hr
https://www.google.com/maps/place/70+Gracechurch+St,+London+EC3V+0XL,+UK/@51.512166,-0.0846439,17z/data=!3m1!4b1!4m5!3m4!1s0x4876035256ab55cb:0x1f93b337c0190cf0!8m2!3d51.512166!4d-0.0846439
Ardel A & Ardel B
Scott & Tracy Clayton
https://find-and-update.company-information.service.gov.uk/company/04240495/persons-with-significant-control
BACHMANN TRUST CORPORATION PLC
BACHMANN CORPORATION LIMITED
CASTLEWOOD TRUST & COMPANY LIMITED - LONDON
http://www.checkcompany.co.uk/company/04240495/CASTLEWOOD-TRUST-%26-COMPANY-LIMITED
Company report 05 20 2021
http://www.checkcompany.co.uk/company-filings/04240495/CASTLEWOOD-TRUST-&-COMPANY-LIMITED
PETER JOHN BACHMANN
MR LESLIE HILTON
MR MARTYN ERIC RUSSELL
https://companycheck.co.uk/director/908416631/MR-PETER-JOHN-BACHMANN/companies
ROUND ENTERPRISES, LTD C/O
BACHMANN TRUST COMPANY LIMITED
is
BACHMANN TRUST COMPANY (UK) LIMITED
Arnold worked @ RP Scherer UK
he joined RP Scherer, a specialist in softgel technologies and now an important part of Catalent, where he served in a variety of international business development and strategi
https://www.biopharma-reporter.com/Article/2011/11/17/News-from-Genzyme-Catalent-and-Futura-People-on-the-move?page=3
Robert Pauli Scherer
https://en.wikipedia.org/wiki/Robert_Pauli_Scherer
We aren't just talking fish gelatin here, Scherer is in my previous Catalent patent posts before today's
Let's go
Jonathan Arnold, swazzzyland
CATALENT NOTTINGHAM LIMITED
https://find-and-update.company-information.service.gov.uk/officers/OFXUlXT6xj_64x-9MgPjRpZIG7E/appointments
https://ch.linkedin.com/in/jonathan-arnold-06a9351?original_referer=&challengeId=AQF3hf87EZ7mfgAAAYCQIl_tmy_FMsXnjaZLywBlaIt0uQ4WbLy3MXzjoyLK_F0bI8fuwsupL_3-JnlBzyIiolnN5RsBPDsK6g&submissionId=19cc2e75-50f7-eb16-5e6b-369b9405da4f
& where is Upperton again
https://www.google.com/maps/dir/Upperton+Pharma+Solutions,+Nottingham,+UK/Catalent+Pharma+Solutions,+8+Orchard+Pl,+Nottingham+NG8+6PX,+United+Kingdom/@52.9614075,-1.249277,13z/data=!3m1!4b1!4m13!4m12!1m5!1m1!1s0x4879c3d77d2fcbcf:0xd102b7eabfd3107e!2m2!1d-1.1831248!2d52.9369731!1m5!1m1!1s0x4879ea48c8dfc2b3:0x75d4bdb75f446dec!2m2!1d-1.241037!2d52.979837
SF twas there
Company address
14, Rue De La Colombiere, Nyon, Switzerland,
http://walkersresearch.com/profilePages/Show_Executive_Title/Executiveprofile/S/Sylvain__Fleury_100004956.html
To the Bertarelli home
https://www.google.com/maps/dir/Tatiana,+1299+Crans-pr%C3%A8s-C%C3%A9ligny,+Switzerland/Rue+de+la+Colombi%C3%A8re+14,+1260+Nyon,+Switzerland/@46.3743967,6.2234161,3059m/data=!3m2!1e3!4b1!4m13!4m12!1m5!1m1!1s0x478c42ca78e834e1:0xa03129c55e332045!2m2!1d6.2244319!2d46.3664569!1m5!1m1!1s0x478c42d8d41d5c39:0xfa9be9bb76cf1580!2m2!1d6.2412838!2d46.3825592
It does but I'll let that one go
No sense in beating a dead horse
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11,224,571.PN.&OS=PN/11,224,571&RS=PN/11,224,571
From that
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220120034305%22.PGNR.&OS=DN/20120034305&RS=DN/20120034305
From that
Harry SEAGER
https://find-and-update.company-information.service.gov.uk/officers/NUS8f1H8Y0oREDrSDk2NzHBMRv4/appointments
From that
https://find-and-update.company-information.service.gov.uk/company/SC070691
From that
https://find-and-update.company-information.service.gov.uk/company/SC070691/filing-history
From that
https://find-and-update.company-information.service.gov.uk/company/SC070691/filing-history
06 Apr 2018 Appointment of Mr Jonathan Arnold as a director on 29 March 2018
View PDF Appointment of Mr Jonathan Arnold as a director on 29 March 2018 - link opens in a new window - 2 pages(2 pages)
https://s3.eu-west-2.amazonaws.com/document-api-images-live.ch.gov.uk/docs/9Pmy7XLC7H4LsuDm-DnDbxDNuMYfXGiAGS0BjoClepc/application-pdf?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAWRGBDBV3CIJW264S%2F20220504%2Feu-west-2%2Fs3%2Faws4_request&X-Amz-Date=20220504T162900Z&X-Amz-Expires=60&X-Amz-Security-Token=IQoJb3JpZ2luX2VjEKz%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCWV1LXdlc3QtMiJHMEUCIQD8iv2tN6NCLYHPhCsZUAw7Zuv9%2FRxTuiagzC85%2F4bfuQIgAKwYwjDn12t%2BGpwnCLJ%2B373RMec7PWf5jfk5ehbmuPgq0wQIdRAEGgw0NDkyMjkwMzI4MjIiDF%2FIfFs2QCR%2Bk%2B45SCqwBH4uKl6pgC1Y%2B0LThjhPYfEzGDhXPqXKi12g5IC0zez1%2FuhPG3j97xStIXC8tH0PNfW2Ewp0x0D4SO%2B00ZFSHR5yWb0fdSzAQaMlrBsoVp%2BNH2cT7d8LaDVNn%2BygFSrCjehc6G7e96bjTkQvQRj3VplXwyNhwC2bq36KVWLvz24BzTnpB9iGrlpZ0aYcezn6xaPc4TYSL0enR6Rpr9FY9nFC8vxO8c3X76upRNXtd7nMShUgFIQW0NCozXYAkBQ76xwW4GRBUMHXSX5xeuNYgF0ar99XIphSF9H3FZI1%2F3adM8aRjj2E2EtXOfNiM9X23JJt5BWlfcLLBPoVt6I9Ki6lxdPqC8dN8m%2BWEA8MlyEwWPDw2%2BJbMATLnw5ClThXzlPDNH7FGVhM27Csaa%2FPX2WjdTx%2FGS4usyPHgYtvHLVrEGXhURXasfbdp5yDrurTWOSXPPUo6NJd9YS%2F6AjkBJqoJ6SMP8Mf4oDXYiDquh3B8IOVHPVuwRdmRfmgnIgRKNVwgxH7vCCx2oanhz4rokiUS13TH3c5ycwv%2FLW3yH2wts%2BMXzPVKZorsEy0NOhF3JFnngP9v33fqOc%2FZqPOLFOcXPV%2F7Jqady3FCL8iaKr3bXE%2B6P877WxMxH%2F6MMvL6MmJxKRVIVexzPNRjFouk9pK0LEC3vn5AdZHqWLgAUcTq5WMdoxS8RNZqxvRFQgZGYk9f0BFfo55bo9KZ3o%2BHQ2PPoeGxc9RQMC6fm0h%2Fh5rMMHJyZMGOqkBn9YECKiMKUn0Xn52wsoSgiQ7uM8oSi0yl%2FRks%2FURoPHpp1ZkTLel8Bwb1hl%2BteCCckzyqvw85OVRonNjYi5POb5NzRd0WUHsIw5uI5fSYl0%2F170m9qJC2t63PPGbWGR3a05KKOw3kojl%2Fco%2BHEJsFTBAWHQSoQVVdpmCeSpnCsa3Zq84X7RSMDXN4ctG5GxU9tw3kvNoFiZIr81B9limIRaxyvDT0saq1w%3D%3D&X-Amz-SignedHeaders=host&response-content-disposition=inline%3Bfilename%3D%22companies_house_document.pdf%22&X-Amz-Signature=0a94c288f7258e013463cb7ed1186e9e537ba47c7fc065b587f5d051023111d1
President Oral Drug Delivery
Show me Nih funding
I'll do that but this is your show....!!!!!!!!
This isn't my place friend b/c my DD is done here
Ronald is the kiss of death, yu are telling me that he let the back door eat his lunch, I don't think so
Jmho
Defense of Mucosal Surfaces: Pathogenesis, Immunity and Vaccines
Jean-Pierre Kraehenbuhl, Marian R. Neutra. Professor Dr. JEAN-PIERRE KRAEHENBUHL Swiss Institute for Experimental Cancer Research Institute of Biochemistry
University of Lausanne
Pg 3
https://books.google.com/books?id=o_bsCAAAQBAJ&pg=PR4&lpg=PR4&dq=Dr.+Marian+R.+Neutra&source=bl&ots=7ixMahwn0E&sig=ACfU3U1ah1y87Bi2GekFpuNm68YrzZRJHw&hl=en&sa=X&ved=2ahUKEwjEiNirt7_3AhWOnXIEHeqzCbQQ6AF6BAgpEAM#v=onepage&q=Dr.%20Marian%20R.%20Neutra&f=false
https://www.unil.ch/ib/en/home/menuinst/research/emeritus-professors/kraehenbuhl-jean-pierre.html
From your lips to
God's ears
hew
Outta here, have a good week
Acknowledgments
This research topic and editorial is dedicated to our former mentor, Dr. Marian R. Neutra, who provided each of us an exceptional training environment in the fields of mucosal immunology, epithelial cell biology and infectious diseases. Her mentorship has influenced how we conduct our own research laboratories and serve as mentors for the next generation of scientists.
https://connects.catalyst.harvard.edu/Profiles/display/Person/72468
https://hms.harvard.edu/news/innate-talent
Top co-authors
Andreas Frey
Research Center Borstel
https://www.researchgate.net/scientific-contributions/Marian-R-Neutra-38462156
Hail Harvard
Likewise, Lakhashe et al. show that systemic priming followed by intranasal boosting with a virosomal HIV-1 gp41 vaccine in nonhuman primates can induce specific antibodies in both serum and vaginal secretions, and confer protection against low dose vaginal SHIV challenge.
Siqi Gong1,2, Samir K. Lakhashe1, Dinesh Hariraju1,2, Hanna Scinto1,3, Antonio Lanzavecchia4,5, Elisabetta Cameroni4,5, Davide Corti4,5, Sarah J. Ratcliffe6, Kenneth A. Rogers2,7, Peng Xiao2, Jane Fontenot2, François Villinger2,7 and Ruth M. Ruprecht1,2,3,7*
1 Texas Biomedical Research Institute, San Antonio, TX, United States
2 New Iberia Research Center, University of Louisiana at Lafayette, Lafayette, LA,United States
3 Department of Microbiology, Immunology, and Molecular Genetics, University of Texas Health San Antonio, San Antonio, TX, United States
4 Institute for Research in Biomedicine, Bellinzona, Switzerland
5 Humabs BioMed, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland
6 University of Pennsylvania, Philadelphia, PA, United States
7 Department of Biology, University of Louisiana at Lafayette, Lafayette, LA, United States
Doesn't that make Mymx worth what Vir {that Gsk & B&MGF has equity in} paid for Humabs BioMed b/c even without knowing that number Mymx is worth way more than it's current stock price which concludes my DD here :}
Later brother
Kadokie
Review Editor for
Mucosal Immunity
https://loop.frontiersin.org/people/42436/overview
Lausanne, Switzerland
https://loop.frontiersin.org/people/25921/overview
Frontiers in Immunology Editorial Office
Frontiers Media SA
Lausanne, Switzerland
https://loop.frontiersin.org/people/20180/overview
Luigi Daniele Notarangelo
Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIH)
Bethesda, United States
Field Chief Editor
Frontiers in Immunology
https://www.frontiersin.org/journals/immunology#
EDITED BY Andreas Frey
Research Center Borstel (LG), Germany
Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
https://www.frontiersin.org/articles/10.3389/fimmu.2022.788619/full
Front. Immunol., 29 April 2022
Editorial: Mucosal Vaccination: Strategies to Induce and Evaluate Mucosal Immunity
Andreas Frey
3 Division of Mucosal Immunology & Diagnostics, Program Area Chronic Lung Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany
https://www.frontiersin.org/articles/10.3389/fimmu.2022.905150/full
Further, he was spokesman for the Innovation Centre for Internationalisation and representative for China, organising the German-Chinese Symposium as well as China and Japan Weeks in Osnabrueck.
https://allfamousbirthday.com/andreas-frey/
Where is Sanders ?
https://www.yahoo.com/news/covid-deaths-no-longer-overwhelmingly-132139645.html
& Ronnie has to put his name on that paper
I'll call him, that is going to happen
Just let me know when you want ?
Thanks
New article! New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes https://t.co/QwileFxmZY #npjvaccines #vaccines pic.twitter.com/WKGJd3Dg9o
— Nicolas Fanget (@nfanget) May 18, 2020
Chris Martin and Jonny Buckland first met each other during their orientation week at University College London in September 1996
2. Materials and Methods
2.1. Cell Lines and Culture Media
Insect Sf-9 (Invitrogen, Waltham, MA, USA), ExpiSf9™ (Thermo Fisher Scientific, Waltham, MA, USA) and SuperSf9-2 (Oxford Expression Technologies, Oxford, UK) cells were routinely sub-cultured at 0.4–1 × 106 cell/mL every 3–4 days when cell density reached 2–5 × 106 cell/mL in 500 mL shake flasks (10% working volume, w/v) in a Innova 44R incubator (orbital motion diameter of 2.54 cm- Eppendorf) at 27 °C and 100 rpm. Sf-900TM II SFM (Thermo Fisher Scientific, Waltham, MA, USA) and ExpiSf TM CD (Thermo Fisher Scientific, Waltham, MA, USA) media were used to culture Sf-9 and SuperSf9-2 cells, and ExpiSf9™ cells, respectively.
Oxford Expression Technologies
https://oetltd.com/about/
Patents Assigned to PARTNERS HEALTHCARE
https://patents.justia.com/assignee/partners-healthcare
Formerly called Partners HealthCare (1994–2020)
In April 2017, the United States District Court for the District of Massachusetts announced that Partners HealthCare System and one of its hospitals, Brigham and Women's Hospital, agreed to pay a $10 million fine to resolve allegations that a stem cell research lab fraudulently obtained federal grant funding.[13]
https://en.wikipedia.org/wiki/Mass_General_Brigham
Intellectual Property Policy
For Partners-Affiliated Hospitals and Institutions
http://healthcare.partners.org/ogcpolicies/ippolicy.pdf
Supported by Chan Zuckerberg
from second link bottom right in last post
https://chanzuckerberg.com/
Subject Area
Infectious Diseases (except HIV/AIDS)
Posted January 11, 2022.
but out for a while
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Facebook on the rise over Elon Musk & Twitter, I hope Facebook gets slaughtered after the close LOL
&
Google Venture Fund supports Sara Gilbert's patent
KIM-1/TIM-1 is a receptor for SARS-CoV-2 in Lung and Kidney
SUMMARY
This study highlights how uptake of SARS-Cov-2 virosomes into human alveolar basal epithelial cells and pig kidney lines was significantly reduced upon blockade of KIM-1. Equally, the uptake of SARS-CoV-2 virosomes increased upon upregulation of KIM-1 on human tubuloids and KIM-1 was shown to bind to SARS-CoV-2 spike protein ectodomain in-vitro. Overall, these observations suggest that KIM-1 may be a receptor for SARS-CoV-2 in both the lung and kidney.
RESEARCH HIGHLIGHTS
KIM-1 was shown to be expressed in the autopsy lung samples of 10/11 patients who had died from SARS-CoV-2 infection; equally, 3 live biopsies of infected patients and 14/30 post-mortem biopsies showed KIM-1 expression
Uptake of fluorescent SARS-Cov-2 virosomes into A549 human alveolar basal epithelial cells was significantly reduced with anti-KIM-1 IgG or with TW-37, an inhibitor of KIM-1 mediated endocytosis; comparable observations were made using mouse primary lung epithelial cells
SARS-CoV-2 virosomes were uptaken into pig kidney lines expressing human KIM-1, an effect that did not occur in controls without KIM-1 expression and that was shown to be independent of ACE2 expression
KIM-1 expressing cells of human three dimensional tubuloids endocytosed SARS-Cov-2 virosomes, and effect that was enhanced when KIM-1 expression was increased
Finally, KIM-1 was shown to bind to the SARS-CoV-2 spike protein ectodomain and GST-RBD in-vitro, with an EC50 of 19nM and 10nM respectively.
IMPACT FOR COVID-19 RESEARCH:
Implies that KIM-1 facilitated endocytosis of SARS-CoV-2 may contribute to the development of acute kidney injury, a major complication of SARS-CoV-2 infection, associated with higher morbidity and mortality of the virus. Given this, targeted treatment directed at KIM-1 may be therapeutic/prophylactic for acute kidney injury occurring secondary to SARS-CoV-2 infection
METHODOLOGIES:
Study Type: In-vitro
Key Techniques: SARS-CoV-2 fluorescent virosomes composed of liposomes conjugate to spike ectodomain; internalization assay of virosomes; human renal tubuloids as a three-dimensional in-vitro model of kidneys
LIMITATIONS:
No assessment of KIM-1 expression of healthy volunteers was assessed, likely due to the difficult of obtaining kidney biopsies from healthy volunteers. Despite clearly shown in-vitro, assessing the contribution of KIM-1 to acute kidney injury using an in-vivo model would have strengthened their claims. Likewise, it would have been interesting to see if blocking KIM-1, either via antibody block or with TW-37, reduced uptake of virosomes into tubuloids.
https://www.immunology.ox.ac.uk/covid-19/covid-19-immunology-literature-reviews/kim-1-tim-1-is-a-receptor-for-sars-cov-2-in-lung-and-kidney
Competing Interest Statement
J.V.B. and T.I. are co-inventors on KIM-1 patents assigned to Partners Healthcare. J.V.B and T.I. have filed a patent for the discovery of TW-37 as inhibitor of KIM-1 to alleviate COVID-19. J.V.B. is a consultant to Aldeyra, Angion, Sarepta and Seattle Genetics, and owns equity in Goldfinch, Innoviva, MediBeacon, DxNow, Verinano, and Autonomous Medical Devices. J.V.B.'s interests were reviewed and are managed by Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict-of-interest policies.
Funding Statement
This work was supported by grants from the National Institute of Health/NCATS/NIDDK UH3TR002155 (J.V.B. & L.P.L.); NIDDK 2R01DK072381 (J.V.B. & L.P.L.), R37DK039773 (J.V.B.) and Postdoctoral Fellowship from Uehara Memorial Foundation (to Y.M.), the Overseas Research Fellowships from Japan Society for the Promotion of Science (to Y.M.) and the Canadian Institutes of Health Research (to G.A.D. and J.D.D.).
https://www.medrxiv.org/content/10.1101/2020.09.16.20190694v2
First Author:
Takaharu Ichimura, PhD
Instructor in Medicine
https://bonventrelab.bwh.harvard.edu/wordpress/current_lab_members/takaharu-ichimura-phd/
https://connects.catalyst.harvard.edu/Profiles/display/Person/16669
Insiders won't enrich themselves
w/o
you
:}
Yah, tranches in that one
was never going to work & the history w/ the sec
Wasn't for me but maybe they can get there after the split
Have a good weekend siar & all
My pleasure
I don't have, sorry. It was gleaned from Mr Kempers response a few years back more like 3 or better from a stock holder inquiry & figured out from the otc certs via his response.
but you can look @ the past otc certs & see how the float changes based on the current stock price around the time of the cert date & his options
He can correct me if I wrong but that is unlikely imho :}
Btw, if you still have that Nashville stock & haven't read it, make sure you read the very recent split news
Later
Should be nothing much new in the float b/c Mr K's options are in the float. When the share price crosses a certain price the float would change from 91 mil to 79 mil b/c it's been listed like that in the past. Roughly where this price just was higher & is right now being 06 to 065 ish cents. Meaning, leveraged overall for all the notes combined not far from right here. A good thing begging the question, has the company matured. The Hiv data would indicate that which drove the buying imho.
So he didn't get that in the first otc cert filing that was just out
However, I do like the conversion terms in the 10.01.20 notes b/c if it ever crosses that, the holder most likely won't be selling if it's going higher.
Thanks for the heads up
Later
A small number of prophylactic VLP-based vaccines are currently commercialized worldwide: GlaxoSmithKline’s Engerix (hepatitis B virus) and Cervarix (human papillomavirus), and Merck and Co., Inc.’s Recombivax HB (hepatitis B virus) and Gardasil (human papillomavirus) are some examples. Other VLP-based vaccine candidates are in clinical trials or undergoing preclinical evaluation, such as influenza virus, parvovirus, Norwalk and various chimeric VLPs. Many others are still restricted to small-scale fundamental research, despite their success in preclinical tests.
https://www.mediconmm.com/current-events/vlpnpv-2022/
Sponsors
Mymetics
Paper of the month
https://isv-online.org/paper/april-2022
2013 MARC GIRARD
https://isv-online.org/isv_fellows_of_year
Catalent will more than likely use the UK plant for non cold storage of Mrna vaccines but when
?
Inventor Anke Luise Wilhelmine HuckriedeJørgen Martin de JongeAntonius Johannes Hendrikus StegmannPieter Joseph SchoenJan Christiaan WilschutCurrent Assignee
The listed assignees may be inaccurate.
Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.Bestewil Holding BV
Virosome-like-particles
https://patents.google.com/patent/US7901920B2/en
https://www.freepatentsonline.com/7901920.html
Research Interests:
My research interests center on the development of vaccines against respiratory viruses, in particular influenza. Integrating knowledge of the relevant correlates of immune protection with recent insights in immunology, in particular mechanisms of innate immunology, my group attempts to take a rational approach towards the design of novel influenza vaccine modalities and formulations. Our research activities can be divided into three major research lines. Using systems immunology techniques we try to find new leads for the development of improved vaccines. Among others, we have set up an in vitro vaccine evaluation system based on human PBMCs which can aid in the selection of promising vaccine candidates. For the generation of universal influenza vaccines we re-evaluate old and design new vaccine formulations containing conserved virus antigens to evoke broadly reactive humoral and cellular immune responses. These activities we pursue in the context of the FP7 Project ‘UNISEC’ of which I am co-coordinator. In collaboration with my colleagues Professor H.W. Frijlink and Dr. W.L.J. Hinrichs from the Department of Pharmacy, University of Groningen, my group works onstabilization of influenza vaccines to increase vaccine shelf life and to enable vaccine administration via new, effective and patient-friendly ways like inhalation and sublingual delivery.
https://www.medizin.uni-muenster.de/fluresearchnet/members/prof-dr-anke-huckriede.html
https://isv-online.org/taxonomy/term/66
Come on Catalent, give us some UK Plant investments
:}
That was reviewed by an Oxford grad
Aimee Molineux
Universal Influenza Vaccines
5-7 September 2022, University of Oxford, Oxford, UK
UIV 2022 Conference Chairman:
Sarah Gilbert (Jenner Institute, University of Oxford, Oxford, UK)
SCIENTIFIC ADVISORY PANEL
Anke Huckriede (University of Groningen, Groningen, The Netherlands)
https://www.mediconmm.com/current-events/uiv-2022/
The virosome concept for influenza vaccines
Anke Huckriede 1, Laura Bungener, Toon Stegmann, Toos Daemen, Jeroen Medema, Abraham M Palache, Jan Wilschut
https://pubmed.ncbi.nlm.nih.gov/16026906/
Reconstituted viral envelopes as delivery vehicles for nucleic acids
CONTRIBUTING AUTHORS
Marijke Holtrop
Wouter ter Veer
Pieter Schoen
Toon Stegmann
Jan Wilschut
Anke Huckriede
https://pure.rug.nl/ws/portalfiles/portal/2766785/contr.pdf
VLPNPV 2022 – Virus-Like Particle & Nano-Particle Vaccines
University of Latvia, Riga, Latvia
20-22 June 2022
DNA/RNA Vaccines
CHUV, Lausanne, Switzerland
10-12 October 2022
New Announcement
CVW 2022 – COVID-19 VACCINES FOR THE WORLD
8-9 September 2022, Richard Doll Building, University of Oxford, Oxford, UK
This new and timely two day international meeting will be devoted to up-to-date developments relating to COVID-19 vaccines currently in use and being developed worldwide to tackle the ongoing COVID-19 pandemic.
COVID-19 VACCINES (CVW 2022) FOR THE WORLD will be aimed at updating the community on the current COVID-19 vaccines in use and those vaccines still under development in the UK, Europe, North America, China and Asia. There will be a focus on the major concerns relating to COVID-19 virus variants and what the requirements will be necessary to enable amended COVID-19 vaccines to counter new virus variants.
There will also be an additional focus, relating to the sister UIV 2022 meeting, on the potential ongoing problems that may arise with seasonal influenza in 2022 and beyond and the clear evidence that the seasonal influenza in the 2020/2021 was minimal during the COVID-19 pandemic in that period.
https://www.mediconmm.com/?option=com_content&view=article&id=261&Itemid=523
Ref 6
https://en.wikipedia.org/wiki/Virosome
b Virosome Biologicals, Ant. Deusinglaan 1, 9713 AV Groningen, The Netherlands
https://www.sciencedirect.com/science/article/pii/S0264410X05004603?via%3Dihub
but Mymetics isn't working on influenza vaccines
Bravo for expert management
LOL
Happy Easter my friend
Data is data does
Who is on the scientific board there from Romania
& who meets the Nih Gmp fella over Gmp in Dec 2020
When that stupid process is 80th on the list
for Horizon
My suggestion is, Ernesto not accustomed to losing money but Amy doesn't like the idea @ all
& the folks behind this are much larger than them imho
Hmmmm
How ??????????????????
Ronald Ronald Ronald
Ronald
It's a process
Question is, should we be buying w/
the gunslinger
Happy Easter Ronald Kempers
& your family
Believe or not
WE SUPPORT YOU
Citations
... The following antigens were used for both IgG and IgA assays: Bio-MPR.03 (MPER) (NEQELLELDKWASLWNWFDITNWLWYIR), MYM gp41 (vaccine gp41 from Mymetics), MYM-P1-PE (P1 from Mymetics), SP62 (MPER-2F5 epitope, QQEKNEQELLEL DKWASLWN), gp41 (recombinant MN, Immunodiagnostics) and for IgA, two antigens that corresponded with decreased HIV-1 risk in RV144 were included: 00MSA 4076 gp140 (clade A gp140), A1.con.env03 140 (consensus clade A gp140) (45,46). Assays were run under GCLP compliant conditions, including tracking of positive controls by Levy-Jennings charts using 21CFR Part 11 compliant software. ...
Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
Article
Full-text available
Feb 2022
Samir K. Lakhashe
Mario Amacker
Dinesh Hariraju
Hemant K. Vyas
Ruth M. Ruprecht
A virosomal vaccine inducing systemic/mucosal anti-HIV-1 gp41 IgG/IgA had previously protected Chinese-origin rhesus macaques (RMs) against vaginal SHIV SF162P3 challenges. Here, we assessed its efficacy in Indian-origin RMs by intramuscular priming/intranasal boosting (n=12/group). Group K received virosome-P1-peptide
&
Omicron's binding to Sotrovimab, Casirivimab, Imdevimab, CR3022, and sera from previously infected or vaccinated individuals
Antibody Points to Possible Weak Spot on Novel Coronavirus
https://directorsblog.nih.gov/tag/cr3022-antibody/
Mechanistic Insights to the Binding of Antibody CR3022 Against RBD from SARS-CoV and HCoV-19/SARS-CoV-2: A Computational Study
https://pubmed.ncbi.nlm.nih.gov/33106140/
Anti-SARS-CoV-2 Antibody CR3022 Binds to Coronavirus Variants
https://absoluteantibody.com/general/cr3022-binds-to-coronavirus-variants/
Armed Forces Research Institute of Medical Sciences
https://www.researchgate.net/figure/Distribution-of-the-Six-Primary-Immune-Response-Variables-in-Infected-and-Uninfected_fig2_223957492
Thanks